Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.38 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3240465 | 0.89 | ROCK2 (0.36) | MAOBGSK3BWDR5ROCK2ROCK1 | |
| SCHEMBL3242282 | 0.88 | MAOB (0.48) | MAOBMAPK1GSK3BWDR5ROCK2 | |
| SCHEMBL13673371 | 0.87 | MAOB (0.42) | MAOBGSK3BMT-CO2 | |
| SCHEMBL3240309 | 0.85 | P2RX7 (0.40) | MAOBMAPK1WDR5ROCK1 | |
| SCHEMBL3232868 | 0.85 | PDE2A (0.48) | CHRM4 | |
| SCHEMBL3243700 | 0.82 | EPHX2 (0.44) | MAPK1 | |
| SCHEMBL3247187 | 0.81 | KLKB1 (0.48) | GSK3BMMP13KLKB1 | |
| SCHEMBL1114523 | 0.80 | MAOB (0.46) | MAOBMAPK1MAPK10PPARGCHRM4 | |
| SCHEMBL3242363 | 0.79 | ROCK1 (0.51) | MAPK1MMP13ROCK2ROCK1CACNA1G | |
| SCHEMBL3247205 | 0.76 | HSD17B13 (0.52) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264471-A1 | Compounds, Compositions and Methods Comprising Triazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | claimed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090264471-A1 | Compounds, Compositions and Methods Comprising Triazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
| US-20090264471-A1 | Compounds, Compositions and Methods Comprising Triazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
| US-20090264471-A1 | Compounds, Compositions and Methods Comprising Triazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | MAOB 3971/4885MAPK1 4285/4885MAPK10 4327/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | MAOB 3971/4885MAPK1 4285/4885MAPK10 4327/4885 |
| US-20090264471-A1 | Compounds, Compositions and Methods Comprising Triazole Derivatives | CFTR, PKD1, PKD2 | MAOB 4364/4885MAPK1 2999/4885MAPK10 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.